NCT00215254

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder

Completed Phase 2/Phase 3 Last updated 18 December 2006

What this trial tests

Phase 2/Phase 3 trial testing quetiapine in Social Anxiety Disorder in 15 participants. Completed in 1 February 2006.

Timeline

1 March 2004

1 February 2006

Quick facts

Lead sponsor	Duke University
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	15
Start date	1 March 2004
Estimated completion	1 February 2006
Sites	1 location across United States

Drugs / interventions tested

• quetiapine (quetiapine) — full drug profile →

Conditions studied

• Social Anxiety Disorder — all drugs for Social Anxiety Disorder →

Sponsor

Duke University

Who can join

Adults 18 to 65, any sex, with Social Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Brief Social Phobia Scale (BSPS)

Sponsor's own description

The purpose of the study is to examine the effectiveness and tolerability of quetiapine for the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be effective and well-tolerated for patients with social anxiety disorder.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Pharmacotherapy for social anxiety disorder (SAnD).
   Williams T, Hattingh CJ, Kariuki CM, Tromp SA, et al · · 2017 · cited 37× · PMID 29048739 · DOI 10.1002/14651858.cd001206.pub3